Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 23,600 shares, a drop of 71.5% from the April 15th total of 82,700 shares. Based on an average daily volume of 546,200 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.3% of the company’s stock are short sold.

Lixte Biotechnology Trading Up 1.1 %

LIXT opened at $2.75 on Friday. The firm’s fifty day simple moving average is $2.93 and its 200 day simple moving average is $2.58. The stock has a market capitalization of $6.19 million, a P/E ratio of -1.01 and a beta of -0.23. Lixte Biotechnology has a 12 month low of $1.58 and a 12 month high of $9.50.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings data on Tuesday, March 19th. The company reported ($0.41) earnings per share (EPS) for the quarter.

Lixte Biotechnology Company Profile

Lixte Biotechnology Holdings, Inc operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.